Ozdemir Yusuf Emre, Kizilcay Burak, Sonmezisik Muge, Tarhan Muhammet Salih, Borcak Deniz, Sahin Ozdemir Meryem, Bayramlar Osman Faruk, Yesilbag Zuhal, Senoglu Sevtap, Gedik Habip, Kumbasar Karaosmanoglu Hayat, Kart Yasar Kadriye
1Department of Infectious Diseases and Clinical Microbiology, Bakırkoy Dr. Sadi Konuk Training Research Hospital, 34140, Istanbul, Turkey.
2Department of Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, 34098, Istanbul, Turkey.
Acta Microbiol Immunol Hung. 2022 Sep 21;69(4):270-276. doi: 10.1556/030.2022.01860. Print 2022 Dec 6.
We aimed to compare vaccinated and unvaccinated patients hospitalized with COVID-19 in terms of disease severity, need for intensive care unit (ICU) admission, and death. In addition, we determined the factors affecting the COVID-19 severity in vaccinated patients. Patients aged 18-65 years who were hospitalized for COVID-19 between September and December 2021 were retrospectively analyzed in three groups: unvaccinated, partially vaccinated, and fully vaccinated.A total of 854 patients were included. Mean age was 47.9 ± 10.6 years, 474 patients (55.5%) were male. Of these, 230 patients (26.9%) were fully vaccinated, 97 (11.3%) were partially vaccinated, and 527 (61.7%) were unvaccinated. Of the fully vaccinated patients, 67% (n = 153) were vaccinated with CoronaVac and 33% (n = 77) were vaccinated with Pfizer-BioNTech. All patients (n = 97) with a single dose were vaccinated with Pfizer-BioNTech. One hundred thirteen (13.2%) patients were transferred to ICU. A hundred (11.7%) patients were intubated and 77 (9.0%) patients died. Advanced age (P = 0.028, 95% CI = 1.00-1.07, OR = 1.038) and higher Charlson Comorbidity Index (CCI) (P < 0.001, 95% CI = 1.20-1.69, OR = 1.425) were associated with increased mortality, while being fully vaccinated (P = 0.008, 95% CI = 0.23-0.80, OR = 0.435) was associated with survival in multivariate analysis. Full dose vaccination reduced the need for ICU admission by 49.7% (95% CI = 17-70) and mortality by 56.5% (95% CI = 20-77). When the fully vaccinated group was evaluated, we found that death was observed more frequent in patients with CCI>3 (19.1 vs 5.8%, P < 0.01, OR = 3.7). Therefore, the booster vaccine especially in individuals with comorbidities should not be delayed, since the survival expectation is low in patients with a high comorbidity index.
我们旨在比较感染新冠病毒（COVID-19）住院的接种疫苗患者和未接种疫苗患者在疾病严重程度、重症监护病房（ICU）收治需求及死亡情况方面的差异。此外，我们还确定了影响接种疫苗患者COVID-19严重程度的因素。对2021年9月至12月期间因COVID-19住院的18至65岁患者进行回顾性分析，分为三组：未接种疫苗组、部分接种疫苗组和完全接种疫苗组。共纳入854例患者。平均年龄为47.9±10.6岁，474例患者（55.5%）为男性。其中，230例患者（26.9%）完全接种疫苗，97例（11.3%）部分接种疫苗，527例（61.7%）未接种疫苗。在完全接种疫苗的患者中，67%（n = 153）接种的是科兴新冠疫苗（CoronaVac），33%（n = 77）接种的是辉瑞-BioNTech疫苗。所有接种单剂疫苗的患者（n = 97）均接种的是辉瑞-BioNTech疫苗。113例（13.2%）患者被转入ICU。100例（11.7%）患者接受了插管治疗，77例（9.0%）患者死亡。高龄（P = 0.028，95%置信区间[CI]=1.00 - 1.07，比值比[OR]=1.038）和较高的查尔森合并症指数（CCI）（P < 0.001，95% CI = 1.20 - 1.69，OR = 1.425）与死亡率增加相关，而在多因素分析中，完全接种疫苗（P = 0.008，95% CI = 0.23 - 0.80，OR = 0.435）与生存相关。全程接种疫苗使ICU收治需求降低了49.7%（95% CI = 17 - 70），死亡率降低了56.5%（95% CI = 20 - 77）。在评估完全接种疫苗组时，我们发现CCI>3的患者死亡更为频繁（19.1%对5.8%，P < 0.01，OR = 3.7）。因此，尤其是合并症患者不应延迟接种加强针，因为合并症指数高的患者生存预期较低。
